Stay updated on Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial

Sign up to get notified when there's something new on the Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating an update in the phase I trial studying the side effects and best dose of mocetinostat when given together with vinorelbine to treat children, adolescents, and young adults with rhabdomyosarcoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:28.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    39%
    Check dated 2024-05-22T21:28:09.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:14:47.000Z thumbnail image

Stay in the know with updates to Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial page.